Cargando…
Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
Krabbe disease is a severe, fatal neurodegenerative disorder caused by defects in the lysosomal enzyme galactocerebrosidase (GALC). The correct targeting of GALC to the lysosome is essential for the degradation of glycosphingolipids including the primary lipid component of myelin. Over 100 different...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons A/S
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949656/ https://www.ncbi.nlm.nih.gov/pubmed/27126738 http://dx.doi.org/10.1111/tra.12404 |
_version_ | 1782443469596262400 |
---|---|
author | Spratley, Samantha J. Hill, Chris H. Viuff, Agnete H. Edgar, James R. Skjødt, Karsten Deane, Janet E. |
author_facet | Spratley, Samantha J. Hill, Chris H. Viuff, Agnete H. Edgar, James R. Skjødt, Karsten Deane, Janet E. |
author_sort | Spratley, Samantha J. |
collection | PubMed |
description | Krabbe disease is a severe, fatal neurodegenerative disorder caused by defects in the lysosomal enzyme galactocerebrosidase (GALC). The correct targeting of GALC to the lysosome is essential for the degradation of glycosphingolipids including the primary lipid component of myelin. Over 100 different mutations have been identified in GALC that cause Krabbe disease but the mechanisms by which they cause disease remain unclear. We have generated monoclonal antibodies against full‐length human GALC and used these to monitor the trafficking and processing of GALC variants in cell‐based assays and by immunofluorescence microscopy. Striking differences in the secretion, processing and endosomal targeting of GALC variants allows the classification of these into distinct categories. A subset of GALC variants are not secreted by cells, not proteolytically processed, and remain trapped in the ER; these are likely to cause disease due to protein misfolding and should be targeted for pharmacological chaperone therapies. Other GALC variants can be correctly secreted by cells and cause disease due to catalytic defects in the enzyme active site, inappropriate post‐translational modification or a potential inability to bind essential cofactors. The classification of disease pathogenesis presented here provides a molecular framework for appropriate targeting of future Krabbe disease therapies. [Image: see text] |
format | Online Article Text |
id | pubmed-4949656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley & Sons A/S |
record_format | MEDLINE/PubMed |
spelling | pubmed-49496562016-07-28 Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants Spratley, Samantha J. Hill, Chris H. Viuff, Agnete H. Edgar, James R. Skjødt, Karsten Deane, Janet E. Traffic Original Articles Krabbe disease is a severe, fatal neurodegenerative disorder caused by defects in the lysosomal enzyme galactocerebrosidase (GALC). The correct targeting of GALC to the lysosome is essential for the degradation of glycosphingolipids including the primary lipid component of myelin. Over 100 different mutations have been identified in GALC that cause Krabbe disease but the mechanisms by which they cause disease remain unclear. We have generated monoclonal antibodies against full‐length human GALC and used these to monitor the trafficking and processing of GALC variants in cell‐based assays and by immunofluorescence microscopy. Striking differences in the secretion, processing and endosomal targeting of GALC variants allows the classification of these into distinct categories. A subset of GALC variants are not secreted by cells, not proteolytically processed, and remain trapped in the ER; these are likely to cause disease due to protein misfolding and should be targeted for pharmacological chaperone therapies. Other GALC variants can be correctly secreted by cells and cause disease due to catalytic defects in the enzyme active site, inappropriate post‐translational modification or a potential inability to bind essential cofactors. The classification of disease pathogenesis presented here provides a molecular framework for appropriate targeting of future Krabbe disease therapies. [Image: see text] John Wiley & Sons A/S 2016-05-30 2016-08 /pmc/articles/PMC4949656/ /pubmed/27126738 http://dx.doi.org/10.1111/tra.12404 Text en © 2016 The Authors. Traffic published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Spratley, Samantha J. Hill, Chris H. Viuff, Agnete H. Edgar, James R. Skjødt, Karsten Deane, Janet E. Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants |
title | Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants |
title_full | Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants |
title_fullStr | Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants |
title_full_unstemmed | Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants |
title_short | Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants |
title_sort | molecular mechanisms of disease pathogenesis differ in krabbe disease variants |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949656/ https://www.ncbi.nlm.nih.gov/pubmed/27126738 http://dx.doi.org/10.1111/tra.12404 |
work_keys_str_mv | AT spratleysamanthaj molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants AT hillchrish molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants AT viuffagneteh molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants AT edgarjamesr molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants AT skjødtkarsten molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants AT deanejanete molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants |